Moreover, MLN4924, while dose-dependently reducing ITGB4 expression (Fig. 4A), also suppressed the migration and invasion of breast cancer cells in a dose-dependent manner (Figs. 5C and S5C). Here, ITGB4 is linked to breast carcinoma.